Latest Content

Preservative-free bimatoprost gel now offers once-daily glaucoma and ocular hypertension IOP reduction, aiming to boost comfort, tolerability, and long-term adherence.

Mile Brujic, OD, FAAO, stated in a poster presentation that a multi-practice study found that the lens had particularly positive effects on patients who reported dryness symptoms.

Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, details the challenges of managing dry eye in contact lens wearers via accurate diagnosis and thoughtful lens fitting.

Mitch Ibach, OD, FAAO, said that medication optimization is key when taking the interventional approach to glaucoma.

The emerging technology offers a new paradigm for treating a group of eye diseases.

Joe Shovlin, OD, FAAO, outlines the management and treatment of corneal infections in one of his Optometry's Meeting presentations.

Mohammad Rafieetary, OD, FAAO, FORS, DipABO, ABCMO, discussed his AOA 2026 presentation "Eye of the Needle Returns: Navigating the Patient’s Journey Receiving Intravitreal Injections."

A cross-sectional study of nearly 10,000 nursing home residents found a clear dose-response relationship between vision loss and cognitive impairment, with blind residents having nearly 3 times the odds of cognitive loss compared with those with normal vision.

A Johnson & Johnson Vision poster found a novel multifocal toric daily disposable contact lens delivered visual acuity within 1 letter and comparable fitting success to an existing nontoric multifocal lens, extending coverage to presbyopes with up to 1.75D astigmatism.

A systematic review of 22 studies found Demodex infestation strongly associated with MGD, with MGD prevalence reaching 92% to 99% in symptomatic Demodex blepharitis and significantly worse meibomian gland structure and function in infested patients.

For Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, myopia management is best started sooner rather than later.

A real-world pilot across 8 optometric sites found Qlosi (0.4% pilocarpine) implementation met or exceeded all corporate KPIs, with UWF imaging utilization rising 16.4 percentage points and 72.7% of patients achieving personal treatment goals.

GATHER2 OLE data through 3.5 years show avacincaptad pegol reduced GA lesion growth by 28.8% in continuously treated patients and 37% to 40% in those switched from sham, with no new safety signals.